Doo Young Jung
Founder & Chief Executive Officer Pinotbio
Doo Young Jung is Founder and Chief Executive Officer of PinotBio, a biotechnology company focused on next-generation ADCs for the treatment of cancer. Trained as a medicinal chemist and intellectual property expert, he previously served as a patent examiner at the Korean Intellectual Property Office and led technology commercialization initiatives at the Korea Research Institute of Chemical Technology. At PinotBio, Dr. Jung has overseen the development of the company’s proprietary ADC platforms, including the PBX-7016 payload technology, while leading business development, global partnerships, and fundraising efforts. His work is dedicated to advancing innovative ADC therapies for patients with difficult-to-treat cancers.
Seminars
- Utilizing PK/PD modeling to understand ADC and payload distribution in-circulation and in-tumor tissue to optimize payload discovery and selection
- Applying AI/ML to tumor target distribution data to inform ideal antibody properties and maximize ADC therapeutic index
- Contextualizing best-in-class ADC development through discovery and preclinical profile of PBX-004
